Skip to main content

ULTRA-DD

Innovative Medicines Initiative LogoEfpia logoEuropean Commission Research and Innovation logo

Search

  • Overview
    • Objectives and disease focus
    • Deliverables
      • Executive Summary 2020 Report
      • Executive Summary 2019 Report
      • Executive Summary 2018 Report
    • Organisation
      • Scientific Committee
      • Leadership
    • Participants
    • News
    • Contact
  • Tissue Platforms
    • Diseases
    • Cell Assay Datasets
  • Probes
    • Chemical Probes
    • Biological probes
  • Antibodies
  • Structures
  • ChromoHub
  • Publications

Open Access Could Transform Drug Discovery: A Case Study of JQ1

  • Read more about Open Access Could Transform Drug Discovery: A Case Study of JQ1

Arshad, Z., Smith, J., Roberts, M., Lee, W. H., Davies, B., Bure, K., … Brindley, D. (2016). Open Access Could Transform Drug Discovery: A Case Study of JQ1. Expert Opinion on Drug Discovery, 11(3), 321-332.

XGR software for enhanced interpretation of genomic summary data, illustrated by application to immunological traits

  • Read more about XGR software for enhanced interpretation of genomic summary data, illustrated by application to immunological traits

Fang, H., Knezevic, B., Burnham, K. L., Knight, J. C. (2016). XGR software for enhanced interpretation of genomic summary data, illustrated by application to immunological traits. Genome Medicine, 8, 129.

A High-Density Map for Navigating the Human Polycomb Complexome

  • Read more about A High-Density Map for Navigating the Human Polycomb Complexome

Hauri, S., Comoglio, F., Seimiya, M., Gerstung, M., Glatter, T., Hansen, K., … Beisel, C. (2016). A High-Density Map for Navigating the Human Polycomb Complexome. Cell Reports, 17(2), 583-595.

Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia

  • Read more about Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia

Picaud, S., Leonards, K., Lambert, J.-P., Dovey, O., Wells, C., Fedorov, O., … Filippakopoulos, P. (2016). Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. Science Advances, 2(10), e1600760.

Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors

  • Read more about Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors

Popp, T. A., Tallant, C., Rogers, C., Fedorov, O., Brennan, P. E., Müller, S., … Bracher, F. (2016). Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors. Journal of Medicinal Chemistry, 59(19), 8889-8912.

Pagination

  • Previous page ‹‹
Subscribe to 2016
The ULTRA-DD project is supported by the Innovative Medicines Initiative Joint Undertaking (IMI JU) under grant agreement n° [115766], resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. This website reflects only the author’s views and neither IMI nor the European Commission is liable for any use that may be made of the information contained therein.
This website is licensed under a CC-BY licence | Accessibility